TCB-006

N/A

Report date: 2022/11/02 18:05:24

Base Information

Drug NameTCB-006

Drug Alias NameB7-H4 CAR-T therapy TCB-006Anti-B7-H4 Car-T therapy TCB-006B7-H4 chimeric antigen receptor γδ T cell therapy (Tc Biopharm)Anti-VTCN1 gamma delta CAR-T cell therapy (Tc Biopharm)TCB-006

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-V-set domain-containing T-cell activation inhibitor 1

TargetsV-set domain-containing T-cell activation inhibitor 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTc Biopharm Ltd

China Registration ClassN/A

Develop Information

Active CompaniesTc Biopharm Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A